Martha Patricia Gallegos-Arreola1, Guillermo Moisés Zúñiga-González2, Josefina Yoaly Sánchez-López1, Alondra Yeraldi Naranjo Cruz1, Valeria Peralta-Leal3, Luis Eduardo Figuera1, Ana María Puebla-Pérez4, Carlos Alberto Ronquillo-Carreón5, Ana Graciela Puebla-Mora6. 1. Genetics Division, Western Biomedical Research Center, Western National Medical Center, Mexican Institute of Social Security, Guadalajara, Jalisco, Mexico. 2. Mutagenesis Laboratory, Molecular Medicine Division, Western Biomedical Research Center, Western National Medical Center, Mexican Institute of Social Security, Guadalajara, Jalisco, Mexico. 3. Facultad de Medicina e Ingeniería en Sistemas Computacionales (FMeISC), Universidad Autónoma de Tamaulipas, Matamoros, Tamaulipas, México. 4. Inmmunopharmacology Laboratory, Exact and Engineering Sciences University Center, University of Guadalajara, Guadalajara, Jalisco, Mexico. 5. UMAE, Specialty Hospital, Oncology Service, Western National Medical Center, Mexican Institute of Social Security, Guadalajara, Jalisco, Mexico. 6. UMAE, Specialty Hospital, Pathology Service, Western National Medical Center, Mexican Institute of Social Security, Guadalajara, Jalisco, Mexico.
Abstract
OBJECTIVE: To examine the association between TYMS 2R3R polymorphism and DPYD [IVS]14+1G>A mutation by comparing healthy subjects with colorectal cancer (CRC) patients in the Mexican population. METHOD: Genotyping of the 2R/3R was performed by polymerase chain reaction (PCR) and [IVS]14+1G>A mutation by real-time PCR analysis. RESULTS: The observed frequencies of the TYMS 2R3R polymorphism and the -[IVS]14+1G>A mutation in DPYD did not indicate an increased risk for CRC (p>0.05). However we observed an association of the 2R/2R (OR 3.08, 95% CI 1.66-6.08, p=0.0017) and heterozygous (OR 1.98, 95% CI 1.32-2.97, p=0.0012) genotypes as risk factors when comparing controls and CRC patients that were also tobacco consumers. An association between the genotype and the disease was evident. The distribution of the 2R/2R genotype and hematological toxicity (adjusted OR 2.26, 95% CI 1.54-4.45, p=0.0259), heterozygous (2R/3R) with tumor stage III-IV (OR 1.81, 95% CI 1.11-2.94, p=0.020) and 2R/2R-2R/3R in non-chemotherapy response CRC patients with hematological (OR 2.3, 95% CI 1.21-4.4, p=0.014) and gastric toxicities (OR 3.11, 95% CI 1.18-8.2, p=0.035) confirmed that this factor may significantly contribute to the CRC susceptibility. CONCLUSION: TYMS 2R3R polymorphism and the -[IVS]14+1G>A mutation in DPYD was not associated with susceptibility to CRC. However, the 2R/2R and 2R/3R genotypes of TYMS polymorphism could significantly contribute to hematological and gastric toxicity in CRC patients in this sample population.
OBJECTIVE: To examine the association between TYMS 2R3R polymorphism and DPYD [IVS]14+1G>A mutation by comparing healthy subjects with colorectal cancer (CRC) patients in the Mexican population. METHOD: Genotyping of the 2R/3R was performed by polymerase chain reaction (PCR) and [IVS]14+1G>A mutation by real-time PCR analysis. RESULTS: The observed frequencies of the TYMS 2R3R polymorphism and the -[IVS]14+1G>A mutation in DPYD did not indicate an increased risk for CRC (p>0.05). However we observed an association of the 2R/2R (OR 3.08, 95% CI 1.66-6.08, p=0.0017) and heterozygous (OR 1.98, 95% CI 1.32-2.97, p=0.0012) genotypes as risk factors when comparing controls and CRC patients that were also tobacco consumers. An association between the genotype and the disease was evident. The distribution of the 2R/2R genotype and hematological toxicity (adjusted OR 2.26, 95% CI 1.54-4.45, p=0.0259), heterozygous (2R/3R) with tumor stage III-IV (OR 1.81, 95% CI 1.11-2.94, p=0.020) and 2R/2R-2R/3R in non-chemotherapy response CRC patients with hematological (OR 2.3, 95% CI 1.21-4.4, p=0.014) and gastric toxicities (OR 3.11, 95% CI 1.18-8.2, p=0.035) confirmed that this factor may significantly contribute to the CRC susceptibility. CONCLUSION:TYMS 2R3R polymorphism and the -[IVS]14+1G>A mutation in DPYD was not associated with susceptibility to CRC. However, the 2R/2R and 2R/3R genotypes of TYMS polymorphism could significantly contribute to hematological and gastric toxicity in CRC patients in this sample population.
Authors: Mohammad Hadi Abbasian; Nafiseh Ansarinejad; Bahareh Abbasi; Masoud Iravani; Tayeb Ramim; Fahime Hamedi; Ali M Ardekani Journal: Avicenna J Med Biotechnol Date: 2020 Jul-Sep
Authors: Hui-Zhu Qiu; Ji Huang; Cheng-Cheng Xiang; Rong Li; Er-Dong Zuo; Yuan Zhang; Li Shan; Xu Cheng Journal: Technol Cancer Res Treat Date: 2020 Jan-Dec